FRATES JAMES M — SEC Form 4 filings
SEC reporting owner CIK 1235598. 18 Form 4 filings on record with FilingPulse; latest filed 2026-09-14.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-01-11 to 2026-09-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 40,000 shares, $101,368 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 8 filings — 51,564 shares, $824,087 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 9,768 shares @ $32.27 ($315,195) in Amylyx Pharmaceuticals, Inc., filed 2026-09-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | 15 | 1 leg · 40,000 sh · $101,368 | 9 legs · 51,564 sh · $824,087 | 11 |
| Sage Therapeutics, Inc. (SAGE) | Director | 3 | — | — | 5 |
Form 4 filings — FRATES JAMES M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-14 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 9,768 @ $32.27 · Sale (S): 1,042 @ $33.23 | EDGAR |
| 2026-08-20 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 22,807 @ $0 | EDGAR |
| 2026-03-09 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 95,990 @ $0 · Grant/award (A): 143,985 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 7,909 @ $14.52 | EDGAR |
| 2026-02-04 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 3,557 @ $14.65 | EDGAR |
| 2026-01-08 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 3,326 @ $11.11 | EDGAR |
| 2025-10-02 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 10,558 @ $14.65 | EDGAR |
| 2025-07-31 | 4 | Sage Therapeutics, Inc. (SAGE) | Code (U): 2,845 · Disposition to issuer (D): 19,154 (derivative) · Disposition to issuer (D): 21,500 (derivative) | EDGAR |
| 2025-06-13 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 10,896 @ $3.47 | EDGAR |
| 2025-03-10 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 68,420 @ $0 · Grant/award (A): 102,630 (derivative) @ $0 | EDGAR |
| 2024-09-16 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Purchase (P): 40,000 @ $2.53 | EDGAR |
| 2024-09-05 | 4/A | Amylyx Pharmaceuticals, Inc. (AMLX) | Option exercise (M): 18,165 @ $6.88 · Option exercise (M): 18,165 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-04-18 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 91,180 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 1,792 @ $18.73 | EDGAR |
| 2024-02-28 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 40,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 2,716 @ $16.33 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-10 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1235598 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →